Literature DB >> 7204886

The influence of subtotal thyroidectomy on the thyroglobulin binding capacity of thyrotoxic serum.

T J Wilkin, J S Beck, A Gunn, R Potts, R J Young.   

Abstract

It has been shown previously that large amounts of thyroglobulin are released into the circulation by the trauma of thyroid surgery. In order to characterize the response to this challenge in patients with and without autoimmune disease, serial estimations of thyroglobulin binding capacity (AgBC) using a sensitive double antibody technique were made on 105 patients undergoing partial thyroidectomy for thyrotoxicosis (70 patients prepared medically) and nontoxic goiter (35 patients). Samples were measured the day before, the day of, and on eight subsequent occasions during the first 14 days after surgery. Three distinct patterns of change in AgBC were observed in the thyrotoxic patients: i) when elevated before surgery, it fell acutely within 48 h of operation and rose again within the first 7-10 days (8 patients); ii) it rose briskly, though transiently, when low (less than 10%) before surgery (4 patients); iii) when elevated before surgery, it rose or fell gently afterwards without sudden change (7 patients). The AgBC in 51 of the Graves' disease patients never exceeded 10% during the perioperative period, and was immeasurably low in all nontoxic goiter patients. Autoimmune thyroid disease results from a disturbance of normal tolerance to thyroid antigens, and thyroid surgery provides an in vivo model in which the response to an acute antigenic challenge may be studied. Patients with Graves' disease showed varying degrees of intolerance to the challenge, while those with nontoxic goiter and no evidence of autoimmune disease were uniformly unresponsive.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7204886     DOI: 10.1007/bf03349376

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

1.  Human autoimmune thyroiditis: serological studies.

Authors:  I M ROITT; D DONIACH
Journal:  Lancet       Date:  1958-11-15       Impact factor: 79.321

2.  IODINE COMPONENTS OF THE BLOOD. CIRCULATING THYROGLOBULIN IN NORMAL PERSONS AND IN PERSONS WITH THYROID DISEASE.

Authors:  J Lerman
Journal:  J Clin Invest       Date:  1940-07       Impact factor: 14.808

3.  Effect of therapy on serum thyroglobulin levels in patients with Graves' disease.

Authors:  R P Uller; A J Van Herle
Journal:  J Clin Endocrinol Metab       Date:  1978-05       Impact factor: 5.958

4.  Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies.

Authors:  A Pinchera; P Liberti; E Martino; G F Fenzi; L Grasso; L Rovis; L Baschieri; G Doria
Journal:  J Clin Endocrinol Metab       Date:  1969-02       Impact factor: 5.958

5.  Kinetic differences in unresponsiveness of thymus and bone marrow cells.

Authors:  J M Chiller; G S Habicht; W O Weigle
Journal:  Science       Date:  1971-02-26       Impact factor: 47.728

6.  Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.

Authors:  A J Herle; R P Uller
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

7.  THYROGLOBULIN IN THE SERUM OF PARTURIENT WOMEN AND NEWBORN INFANTS.

Authors:  E S ASSEM
Journal:  Lancet       Date:  1964-01-18       Impact factor: 79.321

8.  A stable sheep cell preparation for detecing thyroglobulin auto-antibodies and its clinical applications.

Authors:  A J FULTHORPE; I M ROITT; D DONIACH; K COUCHMAN
Journal:  J Clin Pathol       Date:  1961-11       Impact factor: 3.411

9.  Lymphocytes binding human thyroglobulin in healthy people and its relevance to tolerance for autoantigens.

Authors:  A D Bankhurst; G Torrigiani; A C Allison
Journal:  Lancet       Date:  1973-02-03       Impact factor: 79.321

10.  Thyroid antibodies and "thyroglobulin" in the serum in pregnant and parturient women and in newborn infants.

Authors:  T HJORT; G T PEDERSEN
Journal:  Lancet       Date:  1962-08-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.